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Abstract Delayed onset of action of oral P2Y12 inhibitors in ST-elevation myocardial infarction
(STEMI) patients may increase the risk of acute stent thrombosis. Available parenteral
anti-thrombotic strategies, to deal with this issue, are limited by added cost and
increased risk of bleeding. We investigated the pharmacodynamic effects of a novel
regimen of enoxaparin in STEMI patients undergoing primary percutaneous coronary
intervention (PPCI). Twenty patients were recruited to receive 0.75 mg/kg bolus of
enoxaparin (pre-PPCI) followed by infusion of enoxaparin 0.75 mg/kg/6 h. At four time
points (pre-anti-coagulation, end of PPCI, 2–3 hours into infusion and at the end of
infusion), anti-Xa levels were determined using chromogenic assays, ﬁbrin clots were
assessed by turbidimetric analysis and platelet P2Y12 inhibition was determined by
VerifyNow P2Y12 assay. Clinical outcomes were determined 14 hours after enoxaparin
initiation. Nineteen of 20 patients completed the enoxaparin regimen; one patient,
who developed no-reﬂow phenomenon, was switched to tiroﬁban after the enoxaparin
bolus. All received ticagrelor 180 mg before angiography. Mean ( standard error of
themean) anti-Xa levels were sustained during enoxaparin infusion (1.17  0.06 IU/mL
at the end of PPCI and 1.003  0.06 IU/mL at 6 hours), resulting in prolonged ﬁbrin clot
lag time and increased lysis potential. Onset of platelet P2Y12 inhibition was delayed in
opiate-treated patients. No patients had thrombotic or bleeding complications. In
conclusion, enoxaparin 0.75 mg/kg bolus followed by 0.75 mg/kg/6 h provides
sustained anti-Xa levels in PPCI patients. This may protect from acute stent thrombosis
in opiate-treated PPCI patients who frequently have delayed onset of oral P2Y12
inhibition.
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Introduction
Dual oral anti-platelet therapy is essential in patients pre-
senting with ST-elevation myocardial infarction (STEMI) and
undergoing primary percutaneous coronary intervention
(PPCI).1
Potent P2Y12 inhibition, with prasugrel or ticagrelor,
resulted in improved outcomes following acute coronary
syndrome.2,3Although these two agents provide rapidplatelet
inhibition in stable patients,4,5 their onset of action can be
delayed in patients undergoing PPCI, particularly those pre-
treated with opiates such as morphine.6–10 This negative
interactionmight increase the riskofacute stent thrombosis,11
necessitating initial parenteral anti-thrombotic treatment to
cover the period prior to P2Y12 inhibitor absorption.
Available parenteral therapies to deal with this issue
include glycoprotein IIb/IIIa inhibitors (GPIs)12 or intravenous
P2Y12 inhibition with cangrelor.13 However, these options
have several limitations. GPIs increase the risk of major
bleeding events and routine use has resulted in worse out-
comes in several trials.14–17 Cangrelor has some advantages: It
inhibits platelet P2Y12 receptors within 2 minutes and has
rapid offset of action over 1 hour after cessation of infusion.13
However, it has primarily been used as a 2-hour infusion and
thismight not be sufﬁcient in patientswithmore than 2 hours
delay in the onset of oral P2Y12 inhibition. Moreover, the very
rapid offset of action may pose a risk should the infusion be
interrupted. GPIs and cangrelor are costly, another factor that
is likely to limit widespread routine use.
Enoxaparin, a low-molecular-weight heparin, targets fac-
tor Xa and, to a lesser extent, factor IIa (thrombin).18 It has a
half-life of 1.5 to 2 hours when given intravenously19 and
provides more predictable anti-thrombotic effect compared
with unfractionated heparin (UFH), negating the need for
monitoring.20 A bolus dose of 0.5 or 0.75 mg/kg of enox-
aparin can be given to support the PPCI procedure.1 In
addition to blocking coagulation through the formation of
ﬁbrin, heparins inhibit platelet activation by opposing the
action of thrombin,21 which activates platelets via protease-
activated receptors 1 and 4.22 UFH paradoxically increases
platelet reactivity to soluble agonists such as adenosine
diphosphate, representing potentially undesirable effects
in patients undergoing PCI, whereas therapeutic concentra-
tions of enoxaparin have minimal impact on this.23,24
In the ATOLL trial,25 a bolus dose of enoxaparin 0.5 mg/kg
(with additional 0.25 mg/kg for prolonged procedures) in
patients undergoing PPCI resulted in comparable results to a
bolus dose of UFH (50–70 IU/kg with GPIs or 70–100 IU/kg
without GPIs). However, over 75% of all patients received
GPIs. It may, therefore, be more appropriate to use a higher
bolus dose of anti-coagulant when GPIs are not used, as was
previously acknowledgedwhen studying the combination of
UFH with GPI.26
Wehypothesized that an infusion of enoxaparin (0.75mg/
kg/6 h) following a bolus dose of 0.75 mg/kg would provide
sufﬁcient and sustained anti-thrombotic effects to bridge
treatment with oral P2Y12 inhibition in STEMI patients
undergoing PPCI, without the need for GPIs or cangrelor. In
this study, we aimed to assess the pharmacodynamic effects
of this regimen.
Materials and Methods
Study Design
This was a single-centre, single-arm, open-label pharmaco-
dynamic study. All study patients provided informed verbal
consent pre-PPCI followed by written consent as soon as
possible following PPCI according to a protocol approved by
the local research ethics committee and the Medicines and
Healthcare Products Regulatory Agency, UK. The trial was
registered at http://clinicaltrials.gov (unique identiﬁer:
NCT03146858).
In vitro studies of the inhibitory effects of enoxaparin on
thrombin-induced platelet activationwere also performed to
support the rationale for the clinical study. Detailedmethods
and results of these in vitro studies are reported in the
►Supplementary Material (available in the online version).
Study Population and Intervention
Patients presenting with STEMI and accepted for PPCI were
recruited if they met the inclusion and exclusion criteria as
detailed in the ►Supplementary Material (available in the
online version). All patients were pre-treated with ticagrelor
180 mg on arrival to hospital and before angiography. Follow-
ingangiography, an intra-arterial bolusofenoxaparin0.75mg/
kg was administered and an intravenous infusion of 0.75 mg/
kg/6 h was started. For the infusion, enoxaparin (0.75 mg/kg)
was added to 250 mL of normal saline and started through an
infusion pump at a rate of 42 mL/h. We planned to stop the
infusion at 3 hours in cases of signiﬁcant renal impairment
(estimated glomerular ﬁltration rate [eGFR] < 30 mL/min/h).
Only in cases of no-reﬂow was GPI use permitted and enox-
aparin infusion was to be stopped if a GPI was administered.
Concomitant use of other anti-coagulants was prohibited and
patients were excluded if they had received UFH or another
anti-coagulant prior to the procedure.
Blood was collected into citrated tubes at four time
points: pre-anti-coagulation, at the end of PPCI, 2 to 3 hours
into infusion and at the end of infusion. Clinical outcomes
were determined at least 14 hours after initiation of infusion.
Outcomes of interest were any thrombotic or bleeding
complications.
Pharmacodynamic Measurements
Tissue factor was obtained from Stago, recombinant tissue
plasminogen activator (tPA) from Technoclone, sodium
chloride from Sigma-Aldrich and calcium chloride dehydrate
and Tris from Fisher Scientiﬁc.
Plasmawas derived and stored at –80°C until analysis. The
primaryoutcomemeasurewas anti-Xa levels at the three time
pointsduring the infusion.Anti-Xa levelsweremeasuredusing
chromogenic assays utilizing the commercially available
Coamatic kit (Chromogenix) and Sysmex CS-5100 analyser.
Fibrin clot properties were assessed using a validated turbi-
dimetric assay.27,28 Permeation buffer solution (100 mMNaCl,
50 mM Tris, pH 7.4) was used for dilution. A total of 25 μL of
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plasma (in duplicates) was mixed with 75 μL of the activation
and lysis mix (83 ng/mL tPA, 10 pM tissue factor, 17 mM
calcium chloride; ﬁnal concentrations) at 37°C. Multiskan FC
(ThermoScientiﬁc)wasused to readplates every30 seconds at
340 nmuntil lysis ofall samples. Fibrin clot lag time,maximum
turbidity (a measure of ﬁbrin clot density, expressed as arbi-
traryunits [AU]) and lysis time (timetaken for turbidity to drop
by 50%) were recorded.
Platelet P2Y12 inhibition was assessed in whole blood
using the VerifyNow P2Y12 system at least 20 minutes
post-sampling. P2Y12 reactivity units (PRUs) and VerifyNow
% inhibition (determined using the thrombin receptor-acti-
vating peptide channel results as estimated baseline
response) were recorded. Evidence of P2Y12 inhibition was
deﬁned as VerifyNow % inhibition  20%.
Thromboelastometry was performed on a subset of
patients recruited during working hours. This was per-
formed according to the manufacturer’s instructions using
a ROTEM delta analyser and in-tem S reagents (Tem Innova-
tions). Clotting time, clot formation time, amplitude at
10 minutes and maximum clot ﬁrmness were recorded.
Statistical Analysis
A sample size of 19with an α of 0.05 gives this study over 90%
power to detect 25% drop in anti-Xa levels during the 6-hour
infusion. Continuous data are presented asmean  standard
error of the mean or median (interquartile range), as appro-
priate. Categorical data are presented as numbers and pro-
portions. One-way analysis of variance (ANOVA) with
Dunnett’s multiple comparison tests was used for assess-
ment of continuous variables. Effect of anti-emetic treatment
on P2Y12 inhibition was assessed using two-way ANOVA.
Results with p-values of < 0.05 were considered statistically
signiﬁcant. Statistical analyseswere performed using Graph-
Pad Prism 7 for Mac OS X.
Results
Study Population
Twenty patients were recruited with median age of 67 years
(►Table 1). Eighty per cent were males, 45% had anterior
STEMI, all had PPCI through the radial artery approach and
one patient required an intra-aortic balloon pump. All
patients received a loading dose of 180 mg ticagrelor pre-
PPCI, administered as whole tablets. Nineteen patients com-
pleted the full enoxaparin regimen and were included in the
pharmacodynamic analyses. No patient had an eGFR < 30
mL/min. One patient was switched to tiroﬁban due to no-
reﬂow phenomenon after enoxaparin bolus but prior to
starting enoxaparin infusion.
Pharmacodynamic Assessments
Anti-Xa levels peaked at the end of PPCI (1.17  0.06 IU/mL)
and were subsequently sustained both 2 to 3 hours into
infusion (1.01  0.05 IU/mL) and at the end of infusion
(1.003  0.06 IU/mL) (►Fig. 1).
Pre-anti-coagulation, the turbidimetric assay demon-
strated rapid ﬁbrin clot formation with a lag time of
Table 1 Baseline, procedural and treatment characteristics
Variable Value
Age (y, median [IQR]) 67 (57–77)
Male sex (%) 16/20 (80)
Caucasian race (%) 18/20 (90)
Anterior STEMI (%) 9/20 (45)
Smoking (%) 12/20 (60)
Hypertension (%) 9/20 (45)
Diabetes mellitus (%) 3/20 (15)
Chronic kidney disease (%) 3/20 (15)
Previous acute coronary
syndrome (%)
3/20 (15)
Previous PCI (%) 2/20 (10)
Treatment with opiates
(morphine/diamorphine)
18/20 (90)
Pain to balloon time
(min, median [IQR])
205 (131–364)
Call to balloon time
(min, median [IQR])
146 (114–179)
Door to balloon time
(min, median [IQR])
47 (41–65)
Stent length (mm, median [IQR]) 22 (14–30)
Stent diameter (mm, median [IQR]) 3.5 (3–4)
Ticagrelor loading to 1st blood
sampling (min, median [IQR])
20 (10–40)
Ticagrelor loading to 2nd blood
sampling (min, median [IQR])
60 (50–95)
Ticagrelor loading to 3rd blood
sampling (min, median [IQR])
185 (175–220)
Ticagrelor loading to 4th blood
sampling (min, median [IQR])
405 (390–425)
Abbreviations: IQR, interquartile range; PCI: percutaneous coronary
intervention; STEMI: ST-elevation myocardial infarction.
Note: Chronic kidney disease is deﬁned as estimated glomerular ﬁltra-
tion rate (eGFR) < 60 mL/min.
Fig. 1 Anti-Xa levels. A scatter plot demonstrating anti-Xa levels
throughout the studied time points (n ¼ 19). Variance during the infusion
was assessed usingone-way analysis of variance (ANOVA). Six hours versus2
to 3 hours; p ¼ 0.6 and 6 hours versus post-PCI; p ¼ 0.09. Error bars
represent mean  standard error of the mean (SEM).
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165  4.4 seconds. This signiﬁcantly prolonged at the end of
PPCI (431  29 seconds; p ¼ 0.0001 vs. baseline) and
remained prolonged during the infusion at 2 to 3 hours
(395  13 seconds; p ¼ 0.0001) and at the end of infusion
(337  6.6 seconds; p ¼ 0.0001) (►Fig. 2A).
Fibrin clot maximum turbiditymeasuredwas 0.45  0.02
AU pre-anti-coagulation. This signiﬁcantly dropped at the
end of PPCI (0.24  0.02 AU; p ¼ 0.0001 vs. baseline) and
gradually increased during the infusion (0.36  0.03 AU;
p ¼ 0.0012 vs. baseline) returning to baseline at the end of
infusion (0.43  0.02 AU; p ¼ 0.7 vs. baseline) (►Fig. 2B).
Pre-anti-coagulation, lysis time measured 3,161  339 sec-
onds. ThissigniﬁcantlydroppedbytheendofPPCI (2,192  489
seconds; p ¼ 0.001 vs. baseline) and remained low during the
infusion (2,128  256 seconds; p ¼ 0.014 vs. baseline) and at
the end of infusion (2,124  259 seconds; p ¼ 0.009 vs. base-
line) (►Fig. 2C).
Platelet P2Y12 Inhibition
All patientswere P2Y12 inhibitor naive on presentation. Time
from ticagrelor loading to different time points is summar-
ized in ►Table 1.
Using a PRU cut-off of < 208 for evidence of P2Y12 inhibi-
tion, 12/19 patients at the end of PPCI, 3/19 at 2 to 3 hours
and 2/19 patients at 6 hours had no P2Y12 inhibition. The two
opiate-free patients had levels < 208 by end of PPCI
(►Fig. 3A).
Using VerifyNow % inhibition, all but the two opiate-free
patientshad0% inhibitionbyendofPPCI (►Fig. 3B). PoorP2Y12
inhibition remained common in morphine-treated patients
throughout the 6-hour infusionwith 8/19 patients still having
0% inhibition at 6 hours despite treatment with anti-emetics
(metoclopramide  ondansetron) in all but 3 opiate-treated
patients. Treatment with anti-emetics did not affect P2Y12
inhibition (interaction p ¼ 0.26). Only one patient vomited
following ticagrelor’s administration and was subsequently
re-loaded with ticagrelor shortly after PPCI.
Thromboelastometry
Thromboelastometrywasperformed ina subsetof11patients.
Only clotting time was signiﬁcantly prolonged throughout
the infusion, whereas the other parameters were insensitive
totheeffectsofenoxaparin(►SupplementaryFig. S2, available
in the online version).
Clinical Outcomes
None of the patients suffered any thrombotic or bleeding
complication during the follow-upperiod (14–24 hours post-
PPCI).
Discussion
We have studied the pharmacodynamic proﬁle of a novel
enoxaparin regimen in STEMI patients undergoing PPCI and
Fig. 2 The effects of enoxaparin on ﬁbrin clot properties. Scatter plots demonstrating ﬁbrin clot properties pre- and throughout treatment with
enoxaparin. Error bars represent mean  standard error of the mean (SEM). AU, arbitrary unit; PPCI, primary percutaneous coronary
intervention.  denotes p < 0.001,  denotes p < 0.01,  denotes p ¼ 0.01; all compared with baseline (T1) and calculated using Dunnett’s
multiple comparisons tests.
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haveshownthat it results insustainedanti-Xa levels throughout
the 6-hour infusion. This regimen positively modulated ﬁbrin
clot properties, prolonging lag time and improving lysis poten-
tial, indicating the formation of less thrombotic clots.29,30
Inefﬁcient lysis is an independent predictor of cardiovascular
death following MI and so this regimen might help to improve
prognosis.31 The universal prolongation of lag time following
enoxaparin was prominent and consistent throughout, which
may provide a useful functional measure of response to this
therapy. Interestingly, ﬁbrin clot studies provided more con-
sistent data compared with thromboelastometry, suggesting a
higher sensitivity of this method for detecting the anti-throm-
botic effects of enoxaparin.
Delayed absorption of oral P2Y12 inhibitors in STEMI
patients is increasingly recognized by interventional cardiol-
ogists as a stent thrombosis risk. Crushing tablets have been
attempted as a way to accelerate absorption of oral P2Y12
inhibitors.32–35 However, results were marginal and delayed
absorption in a proportion of STEMI patients remains a risk.
Similarly, increasing ticagrelor’s loading dose did not over-
come the problem.36 Therefore, parenteral therapies are likely
to be needed to protect a large majority of patients.
This novel enoxaparin regimen has the advantage of being
simple and easy to implement in an emergency situation.
Enoxaparin is also widely used for many other indications
with good tolerability. Moreover, it is inexpensive and there-
fore likely to offer substantial cost savings when compared
with GPIs or cangrelor.
We should acknowledge the limitations of our study. This is
a single-arm pharmacodynamic study and clinical outcomes
are only reportedaspilot outcomes. Larger randomized studies
are needed to establish the safety and efﬁcacy of the studied
enoxaparin regimen in STEMI patients undergoing PPCI.
Furthermore, platelet P2Y12 inhibition was only studied with
onemethodologyalthoughwehave found thismethodology to
be most discriminatory in the assessment of platelet P2Y12
inhibition.37Our study has sufﬁcient power to detect 25% drop
in anti-Xa levels at the two time points. The degree of variance
in anti-Xa levels is of borderline signiﬁcance (p ¼ 0.058) but
levels at the end of infusion remained therapeutic, resulting in
sustained improvement in ﬁbrin clot lysis potential. A high
percentageofpatientshadpoorplatelet inhibitionby theendof
infusion, which raises the possibility that the duration of
infusion might not be sufﬁcient. However, enoxaparin’s half-
life is approximately 2 hours and more P2Y12 inhibition is
highly likely to be established by 8 hours after loading dose of
ticagrelor. This requires further assessment in future work.
Conclusion
A bolus dose of enoxaparin (0.75 mg/kg) followed by an
infusion of 0.75 mg/kg/6 h results in sustained pharmaco-
dynamic effects throughout the infusion in STEMI patients
undergoing PPCI. The efﬁcacy and safety of this regimen
should be evaluated in larger studies.
What is known about the topic?
• Platelet P2Y12 inhibition is often delayed in opiate-
treated STEMI patients undergoing PPCI.
• This delay in platelet inhibitionmay increase the riskof
stent thrombosis.
• Strategies to manage this risk are needed.
What does this paper add?
• A novel regimen of enoxaparin (0.75 mg/kg bolus
followed by 0.75 mg/kg/6 h) in STEMI patients under-
going PPCI results in sustained anti-Xa levels.
• This regimen positively modulates ﬁbrin clot proper-
ties, prolonging ﬁbrin clot lag time, reducing ﬁbrin clot
density and enhancing lysis potential.
• This regimen may offer an inexpensive solution to the
delayed absorption of oral P2Y12 inhibitors but future
studies are needed to conﬁrm safety and efﬁcacy.
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